Indivior Pharmaceuticals Inc (INDV) financial statements and ratios from SEC XBRL: revenue $1.4B (TTM), net margin 16.9%, revenue growth 4.3% YoY, P/E 12.7. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $1.24B |
| Revenue (TTM) | $1.4B |
| Net Margin | 16.9% |
| Operating Margin (TTM) | 35.6% |
| Net Debt / EBITDA | 0.5 |
| Revenue Growth (YoY) | 4.3% |
| EPS Growth (YoY) | 8300.0% |
| FCF Growth (YoY) | -1428.6% |
| P/E Ratio | 12.7 |
| EV / EBITDA | 9.4 |
| Price / Sales | 3.37 |
| FCF Yield | 6.6% |
| Altman Z-Score | 3.34 (safe) |
| Piotroski F-Score | 3/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
INDV overview · INDV earnings · INDV KPIs · INDV documents · INDV ownership · INDV peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.